tetano
Editor, Senior Moderator
Hum Vaccin Immunother
. 2024 Dec 31;20(1):2376821.
doi: 10.1080/21645515.2024.2376821. Epub 2024 Jul 18. Effectiveness of influenza vaccine among the population in Chongqing, China, 2018-2022: A test negative design-based evaluation
Shuang Yang[SUP] 1 2 [/SUP], Qing Wang[SUP] 1 3 [/SUP], Tingting Li[SUP] 1 3 [/SUP], Jiang Long[SUP] 1 3 [/SUP], Yu Xiong[SUP] 1 3 [/SUP], Luzhao Feng[SUP] 4 [/SUP], Qing Wang[SUP] 4 [/SUP], Yong Zhao[SUP] 2 [/SUP], Jule Yang[SUP] 1 3 [/SUP], Wenge Tang[SUP] 1 3 [/SUP], Huadong Zhang[SUP] 1 3 [/SUP], Li Qi[SUP] 1 3 [/SUP]
Affiliations
Influenza vaccination is the most cost-effective strategy for influenza prevention. Influenza vaccines have been found to be effective against symptomatic and medically attended outpatient influenza illnesses. However, there is currently a lack of data regarding the effectiveness of inactivated influenza vaccines in Chongqing, China. We conducted a prospective observational test-negative design study. Outpatient and emergency cases presenting with influenza-like illnesses (ILI) and available influenza reverse transcription polymerase chain reaction (RT-PCR) were selected and classified as cases (positive influenza RT-PCR) or controls (negative influenza RT-PCR). A total of 7,307 cases of influenza and 7,905 control subjects were included in this study. The overall adjusted influenza vaccine effectiveness (IVE) was 44.4% (95% confidence interval (CI): 32.5-54.2%). In the age groups of less than 6 years old, 6-18 years old, and 19-59 years old, the adjusted IVE were 32.2% (95% CI: 10.0-48.9%), 48.2% (95% CI: 30.6-61.4%), and 72.0% (95% CI: 43.6-86.1%). The adjusted IVE for H1N1, H3N2 and B (Victoria) were 71.1% (95% CI: 55.4-81.3%), 36.1% (95% CI: 14.6-52.2%) and 33.7% (95% CI: 14.6-48.5%). Influenza vaccination was effective in Chongqing from 2018 to 2022. Evaluating IVE in this area is feasible and should be conducted annually in the future.
Keywords: Influenza; case control; public health; test-negative study; vaccine effectiveness.
. 2024 Dec 31;20(1):2376821.
doi: 10.1080/21645515.2024.2376821. Epub 2024 Jul 18. Effectiveness of influenza vaccine among the population in Chongqing, China, 2018-2022: A test negative design-based evaluation
Shuang Yang[SUP] 1 2 [/SUP], Qing Wang[SUP] 1 3 [/SUP], Tingting Li[SUP] 1 3 [/SUP], Jiang Long[SUP] 1 3 [/SUP], Yu Xiong[SUP] 1 3 [/SUP], Luzhao Feng[SUP] 4 [/SUP], Qing Wang[SUP] 4 [/SUP], Yong Zhao[SUP] 2 [/SUP], Jule Yang[SUP] 1 3 [/SUP], Wenge Tang[SUP] 1 3 [/SUP], Huadong Zhang[SUP] 1 3 [/SUP], Li Qi[SUP] 1 3 [/SUP]
Affiliations
- PMID: 39025479
- DOI: 10.1080/21645515.2024.2376821
Influenza vaccination is the most cost-effective strategy for influenza prevention. Influenza vaccines have been found to be effective against symptomatic and medically attended outpatient influenza illnesses. However, there is currently a lack of data regarding the effectiveness of inactivated influenza vaccines in Chongqing, China. We conducted a prospective observational test-negative design study. Outpatient and emergency cases presenting with influenza-like illnesses (ILI) and available influenza reverse transcription polymerase chain reaction (RT-PCR) were selected and classified as cases (positive influenza RT-PCR) or controls (negative influenza RT-PCR). A total of 7,307 cases of influenza and 7,905 control subjects were included in this study. The overall adjusted influenza vaccine effectiveness (IVE) was 44.4% (95% confidence interval (CI): 32.5-54.2%). In the age groups of less than 6 years old, 6-18 years old, and 19-59 years old, the adjusted IVE were 32.2% (95% CI: 10.0-48.9%), 48.2% (95% CI: 30.6-61.4%), and 72.0% (95% CI: 43.6-86.1%). The adjusted IVE for H1N1, H3N2 and B (Victoria) were 71.1% (95% CI: 55.4-81.3%), 36.1% (95% CI: 14.6-52.2%) and 33.7% (95% CI: 14.6-48.5%). Influenza vaccination was effective in Chongqing from 2018 to 2022. Evaluating IVE in this area is feasible and should be conducted annually in the future.
Keywords: Influenza; case control; public health; test-negative study; vaccine effectiveness.